JP2022543062A5 - - Google Patents

Info

Publication number
JP2022543062A5
JP2022543062A5 JP2022506474A JP2022506474A JP2022543062A5 JP 2022543062 A5 JP2022543062 A5 JP 2022543062A5 JP 2022506474 A JP2022506474 A JP 2022506474A JP 2022506474 A JP2022506474 A JP 2022506474A JP 2022543062 A5 JP2022543062 A5 JP 2022543062A5
Authority
JP
Japan
Prior art keywords
cancer
combination pharmaceutical
combination
pharmaceutical according
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022506474A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543062A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/044533 external-priority patent/WO2021022172A1/en
Publication of JP2022543062A publication Critical patent/JP2022543062A/ja
Publication of JP2022543062A5 publication Critical patent/JP2022543062A5/ja
Pending legal-status Critical Current

Links

JP2022506474A 2019-08-01 2020-07-31 Ido阻害剤の投与レジメン Pending JP2022543062A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962881518P 2019-08-01 2019-08-01
US62/881,518 2019-08-01
PCT/US2020/044533 WO2021022172A1 (en) 2019-08-01 2020-07-31 A dosing regimen for an ido inhibitor

Publications (2)

Publication Number Publication Date
JP2022543062A JP2022543062A (ja) 2022-10-07
JP2022543062A5 true JP2022543062A5 (https=) 2024-03-18

Family

ID=72139706

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506474A Pending JP2022543062A (ja) 2019-08-01 2020-07-31 Ido阻害剤の投与レジメン

Country Status (11)

Country Link
US (1) US20210030869A1 (https=)
EP (1) EP4007602A1 (https=)
JP (1) JP2022543062A (https=)
KR (1) KR20220044527A (https=)
CN (1) CN114502196A (https=)
AU (1) AU2020319875A1 (https=)
CA (1) CA3148776A1 (https=)
IL (1) IL290006A (https=)
MX (1) MX2022001133A (https=)
PH (1) PH12022550246A1 (https=)
WO (1) WO2021022172A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
JP5465720B2 (ja) 2008-07-08 2014-04-09 インサイト・コーポレイション インドールアミン2,3−ジオキシゲナーゼの阻害剤としての1,2,5−オキサジアゾール
AU2019392090A1 (en) 2018-12-03 2021-06-17 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
US12122848B2 (en) * 2020-07-09 2024-10-22 The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Compositions and methods for treating fibroids
TW202241441A (zh) * 2020-12-29 2022-11-01 美商英塞特公司 包含a2a/a2b抑制劑、pd-1/pd-l1抑制劑及抗cd73抗體之組合療法
CA3224640A1 (en) 2021-07-09 2023-01-12 Krishnan SAMPATHKUMAR Pharmaceutical compositions of a pd-1 antibody and use of the same
MX2024001834A (es) * 2021-08-13 2024-05-15 Agensys Inc Metodos para tratar el cancer de vejiga no muscular invasivo (nmibc) con conjugados de anticuerpos y farmacos (adc) que se unen a las proteinas 191p4d12.
WO2026026944A1 (zh) * 2024-08-02 2026-02-05 应世生物科技(南京)有限公司 新用途

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
PT1107964E (pt) 1998-08-11 2010-06-11 Novartis Ag Derivados de isoquinolina com actividade inibidora da angiogénese
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
BR0212760A (pt) 2001-09-19 2004-12-07 Aventis Pharma Sa Compostos quìmicos
DE60213842T2 (de) 2001-10-30 2007-09-06 Novartis Ag Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung
MXPA04005939A (es) 2002-01-22 2005-01-25 Warner Lambert Co 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1639014B1 (en) 2003-06-13 2010-09-22 Biogen Idec MA Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
AU2005309019A1 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
EA201001030A1 (ru) 2007-12-19 2011-02-28 Амген Инк. Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
JP5465720B2 (ja) 2008-07-08 2014-04-09 インサイト・コーポレイション インドールアミン2,3−ジオキシゲナーゼの阻害剤としての1,2,5−オキサジアゾール
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
MX338327B (es) 2010-10-25 2016-04-12 G1 Therapeutics Inc Inhibidores de cdk.
EP2937349B1 (en) 2011-03-23 2016-12-28 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
ES2799582T3 (es) 2013-11-08 2020-12-18 Incyte Holdings Corp Proceso para la síntesis de un inhibidor de indoleamina 2,3-dioxigenasa
HUE068868T2 (hu) 2015-07-30 2025-02-28 Macrogenics Inc PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
WO2017079669A1 (en) * 2015-11-04 2017-05-11 Incyte Corporation Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor
MX2018014950A (es) * 2016-06-07 2019-04-25 Macrogenics Inc Terapia de combinacion.
US11813280B2 (en) * 2018-01-05 2023-11-14 Dicerna Pharmaceuticals, Inc. Reducing beta-catenin and IDO expression to potentiate immunotherapy

Similar Documents

Publication Publication Date Title
JP2022543062A5 (https=)
CN109963592B (zh) Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途
JP2019517549A5 (https=)
JP2021513540A5 (https=)
JP2019519499A5 (https=)
CN111065411A (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
JP2017514795A5 (https=)
JP2023516441A5 (https=)
JP2022512851A5 (https=)
JP2021511372A5 (https=)
CN111132696A (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
JP2023510199A5 (https=)
JP2023515675A5 (https=)
JP2019524714A5 (https=)
JP2019532970A5 (https=)
US12053530B2 (en) Plectin-1 binding antibodies and uses thereof
TWI870592B (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
CN120437288A (zh) 治疗卵巢癌的药物组合
JP2023500480A5 (https=)
JP2024521105A5 (https=)
JP2021518348A5 (https=)
CN115698076A (zh) 用于治疗肿瘤的药物
JP2022547061A5 (https=)
JP2023531090A5 (https=)
CN120437318A (zh) 抗体药物偶联物和免疫检查点抑制剂的联合应用